The Pharmaceutical Benefits Advisory Committee (PBAC) will soon decide if Enhertu (trastuzumab deruxtecan) should be funded on the PBS for people whose metastatic breast cancer is hormone-receptor positive and HER2-low or HER2-ultralow—without having to have chemotherapy first.  

If you have hormone-positive metastatic breast cancer we’d love you to take part in our short survey about Enhertu.

We would love to hear from people who have already accessed Enhertu and those who might be able to access it in the future if they are found to be HER2-low or HER2-ultralow.

The survey is open until Monday 19 January 2026.